|CrossRef Text and Data Mining|
|Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.|
|Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer|
|Ji-Young Yoon, Yu-Jin Koo, Mi-Jung Kim, Tae-Jin Kim, Kyung-Taek Lim, Ki-Heon Lee|
Obstet Gynecol Sci. 2014;57(6):484-491. Published online November 20, 2014
Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
Re: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase II trial.” — Proposal of a clinical trial of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer, the CHORINE study.
Feasibility of intraoperative intraperitoneal chemotherapy with paclitaxel in patients with epithelial ovarian cancer
A preliminary report on the toxicity and pharmacokinetics of combination systemic and intraperitoneal chemotherapy in advanced epithelial ovarian cancer
Is there a survival benefit associated with intraperitoneal chemotherapy after neoadjuvant chemotherapy for optimally debulked epithelial ovarian cancer patients?
Cytoreductive Surgery and Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer
Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer
Rate and patterns of recurrence in patients undergoing intraperitoneal chemotherapy for advanced epithelial ovarian cancer
Patient factors associated with completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer